Advertisement

Picture BIO Deutschland CFO-Gipfel 2017 Hannover April 600x60px
Document › Details

SuppreMol GmbH. (5/21/13). "Press Release: SuppreMol Raises €9.5 Million in Extended Series D Financing Round". Munich.

Organisations Organisation SuppreMol GmbH
  Group Baxter (Group)
  Organisation 2 MIG Fonds (Group)
Products Product SM101
  Product 2 venture capital
Index term Index term SuppreMol–SEVERAL: investment, 201305 financing round Series D 2nd closing €9.5m
Persons Person Schollmeier, Klaus (SuppreMol 201304– Managing Director before Santhera CEO + ING BHF-Bank + Abbott/Knoll/BASF)
  Person 2 Hecht, Thomas (Delenex 201105 Board Chairman + Affimed 201112 Board Chairman)
     


SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapies for the treatment of autoimmune diseases, today announced the second closing of a series D financing round receiving € 9.5 million.

The second closing of this series D round was again led by MIG AG (Munich, Germany) and Santo Holding GmbH (Holzkirchen, Germany) with BioMedPartners AG (Basel, Switzerland) as co-lead investors; Max Planck Society and FCP Biotech Holding GmbH invested also in this round. Together with the first closing from September 2012 of € 6.5 million, the total of this series D round is now € 16 million.

SuppreMol will use the funds to further advance the Phase II studies of its lead candidate SM101, a recombinant human soluble Fc-gamma receptor IIB (FcgRIIB) for the treatment of Primary Immune Thrombocytopenia (ITP) and of Systemic Lupus Erythematosus (SLE). ITP is a serious bleeding condition characterized by deficient blood clotting due to auto-antibodies destroying the body's platelets. SM101 has been granted orphan drug designation for the treatment of ITP in the EU and US and started Phase IIa clinical studies late last year. SLE is a chronic inflammatory autoimmune disease of unknown etiology affecting multiple organs, which can lead to organ failure.

"I am impressed by the strong commitment of our investors", said Dr. Klaus Schollmeier, who joined SuppreMol as CEO at the beginning of April 2013. "The financing round will enable us to advance our lead product SM101 in Phase II trials and further deepen our knowledge regarding the FcgRIIB-platform."

"This financing round signals strong confidence from our investors in SuppreMol and its lead product SM101," said Dr. Thomas Hecht, Chairman of the Advisory Board. "The additional funding will enable the company to push clinical trials towards the next value enhancing milestones."


About SuppreMol

SuppreMol GmbH is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune and allergic diseases. The company is pioneering the development of soluble Fc-gamma receptors (FcgRs), which are recombinant autologous therapeutic proteins with a specific immunoregulatory potential. The company's lead product SM101, a recombinant soluble FcgRIIB is in Phase II clinical development for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) and has potential to treat Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol's pipeline also includes two antibody development programs utilizing the inhibitory effect of FcgRIIB suitable for alternative treatment strategies and indications. SuppreMol was founded as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has raised about € 51 million through private investors. Major shareholders in the company include MIG Fonds, BioMedPartners AG, Santo Holding GmbH and FCP Biotech Holding GmbH along with KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society, and Z-Cube.


Contact

SuppreMol GmbH

Dr. Klaus Schollmeier
Chief Executive Officer

Tel: +49 89 30 90 50 680
E-mail: info@suppremol.com
www.suppremol.com

   
Record changed: 2016-03-20

Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px

More documents for Baxter (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture BIO Deutschland CFO-Gipfel 2017 Hannover April 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px